| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
Meglumine does not have a specific therapeutic target. Its role in pharmaceutical formulations is physicochemical rather than pharmacological. As an organic base, it reacts with acidic drugs to form water-soluble salts, enhancing their bioavailability and enabling parenteral administration. It acts as a solubilizing agent by increasing the aqueous solubility of poorly soluble compounds. It also functions as a pH-adjusting agent to maintain the stability and compatibility of formulations.
|
|---|---|
| ln Vitro |
Meglumine is not typically evaluated for in vitro biological activity in the same way as a drug. Its in vitro behavior is characterized by its physicochemical properties, such as its ability to increase the solubility of a model drug in aqueous solutions. Its compatibility with various active pharmaceutical ingredients and excipients is assessed in formulation development studies. It is considered an inert excipient with no inherent pharmacological activity.
|
| ln Vivo |
Meglumine is not used for its own pharmacological effects in vivo. Its in vivo role is to facilitate the delivery of an active pharmaceutical ingredient. For example, when used as a counterion for iodinated contrast agents, it improves the agent's solubility and tolerability for intravenous administration. It is rapidly cleared from the body after administration. Its pharmacokinetics are typically dictated by the drug it is formulated with, rather than by meglumine itself.
|
| Enzyme Assay |
Non-cell-based assays for Meglumine are not typical, as it is an excipient. However, its identity and purity are assessed using analytical techniques such as HPLC, GC, and titration. Its melting point (129-131.5°C) is also a key quality control parameter. The formation of salts with organic acids can be studied using techniques like X-ray diffraction or thermal analysis.
|
| Cell Assay |
Cellular assays for Meglumine are not typically performed, as it is an excipient with no pharmacological activity. However, its biocompatibility and potential cytotoxicity can be assessed in cell culture models, particularly when evaluating its safety for parenteral use. In these assays, cells are treated with Meglumine, and cell viability and function are measured.
|
| Animal Protocol |
In vivo animal models for Meglumine are not typically performed for the compound itself, as it is an excipient. However, it is evaluated as part of the formulation of a drug in animal studies. In these studies, the pharmacokinetics, safety, and efficacy of the drug are assessed, and the role of meglumine as a solubilizer or pH adjuster is considered.
|
| ADME/Pharmacokinetics |
Meglumine has a molecular weight of 195.21 g/mol and a molecular formula of C₇H₁₇NO₅. Its CAS number is 6284-40-8. It is a white, crystalline powder with high water solubility. Melting point is 129-131.5°C. Purity is typically ≥98%. Storage conditions: room temperature, protected from moisture. The compound is supplied for research use only.
|
| Toxicity/Toxicokinetics |
Meglumine is generally regarded as a nontoxic material at the levels usually employed as an excipient. It is widely used in parenteral pharmaceutical formulations. The compound is intended for research use only and is not for human consumption. Standard laboratory safety precautions should be followed when handling the compound.
|
| References |
|
| Additional Infomation |
N-Methylglucosamine is a hexosamine, a derivative of D-glucitol, in which the hydroxyl group at position 1 is replaced by a nitrogen atom of a methyl amino group. It is a crystalline base used to prepare salts of certain acids, which can be used as diagnostic radiocontrast agents; its antimonate salt is used as an antigenic drug in animals for the treatment of leishmaniasis. It is a hexosamine and also a secondary amino compound. 1-Deoxy-1-(methylamino)-D-glucitol is a derivative of sorbitol, in which the hydroxyl group at position 1 is replaced by a methyl amino group. It is often used in combination with iodinated organic compounds as a contrast agent.
Meglumine is also known as N-methyl-D-glucamine. It is an organic base used as a pH-adjusting agent and solubilizing agent, primarily in the preparation of soluble salts of iodinated organic acids used as X-ray contrast media. It is widely used as a pharmaceutical excipient. Its CAS number is 6284-40-8. |
| Molecular Formula |
C7H17NO5
|
|---|---|
| Molecular Weight |
195.21
|
| Exact Mass |
195.11
|
| CAS # |
6284-40-8
|
| PubChem CID |
8567
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
490.4±45.0 °C at 760 mmHg
|
| Melting Point |
128-132ºC
|
| Flash Point |
251.6±19.3 °C
|
| Vapour Pressure |
0.0±2.8 mmHg at 25°C
|
| Index of Refraction |
1.555
|
| LogP |
-3.37
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
13
|
| Complexity |
134
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
O([H])[C@]([H])([C@]([H])(C([H])([H])N([H])C([H])([H])[H])O[H])[C@@]([H])([C@@]([H])(C([H])([H])O[H])O[H])O[H]
|
| InChi Key |
MBBZMMPHUWSWHV-BDVNFPICSA-N
|
| InChi Code |
InChI=1S/C7H17NO5/c1-8-2-4(10)6(12)7(13)5(11)3-9/h4-13H,2-3H2,1H3/t4-,5+,6+,7+/m0/s1
|
| Chemical Name |
(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol
|
| Synonyms |
N-Methyl-D-glucamine; Iosulamide; 1-Deoxy-1-(methylamino)-D-glucitol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~50 mg/mL (~256.13 mM)
DMSO : ~10 mg/mL (~51.23 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (512.27 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.1227 mL | 25.6134 mL | 51.2269 mL | |
| 5 mM | 1.0245 mL | 5.1227 mL | 10.2454 mL | |
| 10 mM | 0.5123 mL | 2.5613 mL | 5.1227 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
